The Discovery That Changes Everything About Heart Repair
A team of researchers from the University of Sydney has made headlines with a world-first finding: human heart muscle cells, known as cardiomyocytes, can divide and regenerate after a heart attack. Published in the prestigious journal Circulation Research on December 4, 2025, this study challenges decades-old beliefs that adult human hearts cannot repair themselves through new cell growth. Led by Dr. Robert Hume from the Westmead Institute for Medical Research (WIMR) and supervised by Professor James Chong, the research provides direct evidence of intrinsic cardiomyocyte mitosis—the process where cells divide—following myocardial infarction (MI), the medical term for a heart attack.
This breakthrough comes at a critical time, as cardiovascular disease (CVD) remains Australia's leading cause of death. According to the Heart Foundation, CVD claims one life every 12 minutes, with heart disease specifically killing one person every 18 minutes or 79 people daily. Over 1.3 million Australian adults live with heart-related conditions, underscoring the urgency for regenerative solutions.
Why Heart Regeneration Has Been Elusive Until Now
Traditionally, scientists thought that after birth, cardiomyocytes largely exit the cell cycle, meaning they stop dividing. Post-heart attack, the damaged area scars over with non-functional tissue, leading to heart failure in many survivors. Animal studies, particularly in rodents and zebrafish, hinted at regeneration potential, but human evidence was lacking or controversial due to technical challenges in detecting rare dividing cells.
Australian researchers bridged this gap by analyzing human heart tissue from transplant patients. Explanted hearts—those removed during transplants—provided a unique window: comparing scar-free regions to post-MI scarred areas. This real-world human data contrasts with lab-engineered models, offering robust proof that our hearts attempt self-repair, albeit insufficiently to fully recover.
The study's innovation lies in single-nucleus RNA sequencing (snRNAseq), a cutting-edge technique that profiles gene expression in individual cell nuclei. This revealed 'cycling cardiomyocytes' (CycCM)—cells actively undergoing mitosis—significantly elevated in injured regions.
Behind the Scenes: The University of Sydney's Cardiac Regeneration Lab
At the heart of this discovery is the Cardiac Regeneration Group at WIMR, part of the University of Sydney's Faculty of Medicine and Health. Dr. Robert Hume, a bioengineer with a PhD from the University of Cambridge, leads translational research efforts. Professor James Chong, an interventional cardiologist and lab head, brings clinical insight, having pioneered stem cell therapies for heart repair.
Their collaboration exemplifies Australia's strength in biomedical higher education. The University of Sydney, consistently ranked among the top globally for medicine, invests heavily in such interdisciplinary work. Collaborators included experts from the University of Western Australia, highlighting national teamwork.
"Our research shows that while the heart is left scarred after a heart attack, it produces new muscle cells, which opens up new possibilities," said Professor Chong. Dr. Hume added, "This is the first direct demonstration of cardiomyocyte proliferation in the human heart post-injury."
Unpacking the Study: Methods, Data, and Key Findings
The team examined 14 explanted hearts: seven with remote MI (damage away from transplant site) and seven controls without infarction. Using snRNAseq on over 100,000 nuclei, they identified CycCM markers like TOP2A and MKI67, genes active during cell division.
Results were striking: CycCM frequency rose from 0.35% in healthy tissue to 1.27% in post-MI regions—a nearly fourfold increase. Spatial analysis confirmed these cells clustered near scars. Further validation with immunofluorescence showed mitotic figures—visual proof of dividing cardiomyocytes.
- Increased expression of cell cycle genes in cardiomyocytes post-MI
- Mononuclear cardiomyocytes (capable of division) predominated among CycCM
- No evidence of non-cardiomyocyte contamination, ruling out false positives
These findings, detailed in the paper Human Hearts Intrinsically Increase Cardiomyocyte Mitosis After Myocardial Infarction, set a new benchmark for regeneration research.
Implications for Treating Heart Failure in Australia
Heart failure affects over 500,000 Australians, with limited options beyond transplants. This study suggests the heart's dormant repair mechanism could be amplified pharmacologically. Drugs targeting cell cycle re-entry, like those modulating YAP/TAZ pathways or cyclin-dependent kinases, are now viable.
In Australia, where ischaemic heart disease caused 17,331 deaths in 2021 (10.1% of total), therapies boosting regeneration could save thousands. Professor Chong's group previously healed scars using tropoelastin; combining this with proliferation induction holds promise.
Stakeholder views vary: The Heart Foundation hails it as 'transformative,' while clinicians caution on scaling to trials. Patients stand to gain most, potentially avoiding lifelong medications.
Australia's Growing Hub for Cardiac Research Excellence
Universities like Sydney, Melbourne, and institutions such as Victor Chang Cardiac Research Institute and Heart Research Institute lead globally. Funding from the National Health and Medical Research Council (NHMRC) supports over 200 cardiac projects annually.
This study reinforces Australia's edge: home to pioneers like the late Victor Chang, whose legacy drives innovation. For higher education, it attracts international talent, boosting PhD programs in regenerative medicine.
Explore opportunities at Australian university jobs or research positions in biomedicine.
Challenges in Turning Discovery into Therapy
While exciting, hurdles remain. Proliferation is limited—4x increase isn't enough to replace lost cells (up to 1 billion per MI). Risks include arrhythmias from uneven regeneration or cancer from unchecked division.
Translating to clinics requires large animal models, then human trials. Ethical sourcing of explanted tissue limits samples. Yet, Australian researchers' snRNAseq expertise positions them well.
- Enhance CycCM yield with gene therapy
- Safety profiles for proliferation drugs
- Integration with existing treatments like stents
Career Paths in Heart Regeneration Research
This field booms with jobs: postdocs, research assistants, and faculty roles at Sydney's WIMR or Baker Heart and Diabetes Institute. Skills in bioinformatics, stem cells, and imaging are prized.
Recent listings include cardiac MRI PhDs and research officers. Aspiring scientists can start with research assistant jobs or career advice for Australian researchers.
Australia's ecosystem—with NHMRC grants and collaborations—offers stability amid global funding cuts.
Photo by Florencia Lewis on Unsplash
Global Ripple Effects and Future Outlook
Beyond Australia, this validates human regeneration potential, inspiring US and European labs. Projections show CVD deaths rising 73% by 2050; regenerative meds could counter this.
Next: Chong Lab trials proliferation enhancers in pigs. Long-term, personalized therapies based on patient genetics.
For more, visit the University of Sydney announcement or Heart Foundation stats.
Wrapping Up: A New Era for Heart Health
The University of Sydney's breakthrough illuminates a path from scar to strength. As research accelerates, Australians gain hope—and opportunities. Check higher ed jobs, university positions, rate your professors, or career advice to join this revolution. Share your thoughts below.
